Characteristic features of cigarette smoke exposure, such as lipid accumulation in macrophages, IL-1 and GM-CSF production, and neutrophil recruitment were recapitulated by delivery of damaged lipids to the lungs [10]. non-pathogenic, and possibly protective, function of a newly identified autoantibody induced by chronic cigarette smoke exposure. Background Cigarette smoking is a complex pulmonary TAK-901 insult causing chronic lung inflammation and lung degenerative diseases such as chronic obstructive pulmonary disease (COPD). A hallmark of advanced COPD, and mice chronically exposed to cigarette smoke, is the formation of tertiary lymphoid tissues (TLTs) in the lungs. These immune structures consist of B and T cells, as well as dendritic cells and macrophages [1C3]. The development of TLTs within the lungs suggests local activation of adaptive immune processes that may generate effector T cells as well as antibody production [4]. In fact, indicators of T cell clonal growth and autoantibody production within the lungs have been identified in humans and animal models [3, 5C9]. However, the role of these adaptive immune processes has yet to be fully comprehended. We recently reported that damaged pulmonary lipids play an important role in triggering innate inflammatory responses elicited by cigarette smoke [10]. Characteristic features of cigarette smoke exposure, such as lipid accumulation in macrophages, IL-1 and GM-CSF production, and neutrophil recruitment were recapitulated by delivery of damaged lipids to the lungs [10]. The role of oxidized lipids in inducing inflammatory processes and the accumulation of lipid-laden macrophages are key features shared with KLHL22 antibody atherosclerosis [11C14]. With regard to the adaptive immune system, atherosclerosis is associated with an increase in antibodies against oxidized low-density lipoprotein (OxLDL), TAK-901 largely recognizing the oxidized phospholipid fraction of the macromolecules [15]. Current evidence suggests that these anti-OxLDL antibodies appear to have detrimental as well as beneficial effects on disease pathogenesis [12C15]. As both smoking-induced lung injury and atherosclerosis are driven, in part, by chronic damage to lipids, it is plausible that prolonged cigarette smoke exposure similarly triggers an adaptive response towards oxidized lipids. We therefore hypothesized that chronic cigarette smoke exposure leads to the production of antibodies against oxidized lipids, and that these antibodies may contribute to limit the magnitude of the response towards damaged pulmonary lipids. To test this hypothesis, we used a well-characterized mouse model of cigarette smoke exposure characterized by rapid and persistent activation of innate immune processes, followed by induction of adaptive immune responses [10, 16, 17]. We found that chronic exposure to cigarette smoke led to the induction of antibodies against oxidized LDL in the lungs. Moreover, delivery of a mouse monoclonal antibody against oxidized phosphatidylcholine (OxPC) during acute smoke exposure reduced some inflammatory markers, and increased lipid and particle uptake by pulmonary macrophages. Altogether, this is the first report to document the presence of antibodies against oxidized LDL following chronic smoke exposure and its link to a nonpathogenic, and possibly protective, function in the lungs. Methods Cigarette smoke exposure and interventions Six to 8?week aged female C57BL/6, BALB/c, and A/J mice were exposed to cigarette smoke using a well-characterized whole-body exposure system for 1?h, twice a day, 5?days per week for up to 24?weeks [10, 16, 17]. Control groups were exposed to room TAK-901 air. The Animal Research Ethics Board of McMaster University approved all experimental procedures (Animal Utilization Protocol 07-09-57). A monoclonal IgM antibody against oxidized phosphatidylcholine (clone E06, Avanti Polar Lipids, Alabaster, AL, USA) or a mouse IgM isotype control (clone MM-30, Biolegend, San Diego, CA, USA), was delivered intranasally (20?g in 35?l of sterile PBS) every day 1?h prior TAK-901 to the first cigarette smoke exposure, or at a similar time for cessation experiments. Assessment of bronchoalveolar lavage cells and mediators Mice were anesthetized with isoflurane and euthanized by exsanguination. Lungs were removed from the chest cavity and the trachea canulated. Bronchoalveolar lavage (BAL) was performed by lavaging the lungs twice with 500?l of sterile cold PBS. Total cell concentration was determined using a hemacytometer. The BAL was then centrifuged at 800?g for 8?min. Cytospins were prepared from the resuspended cell pellet and the differential counts performed by counting at least 300 cells per cytospin. Levels of monocyte chemoattractant protein-1 (MCP-1), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin 1 alpha (IL-1) were measured in the BAL fluid by ELISA according to the manufacturers instructions (MCP-1 and IL-1 : R&D Biosystems, Minneapolis, MN, USA; GM-CSF: eBioscience Inc., San Diego, CA, USA). Measurement of antibodies with affinity for oxidized LDL Antibodies TAK-901 against oxidized LDL (OxLDL) were measured in the mouse BAL fluid. Nunc-immuno Multisorp plates were coated overnight at 4?C with 2?g of human OxLDL (AlfaAesar, Heysham, UK) per well in 100?l of PBS. Wells were washed 3 times with PBS-T and then blocked with PBS-T-BSA.